MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.02
-0.17
-1.85%
After Hours: 9.14 +0.12 +1.33% 17:19 07/29 EDT
OPEN
9.27
PREV CLOSE
9.19
HIGH
9.42
LOW
9.01
VOLUME
312.42K
TURNOVER
--
52 WEEK HIGH
15.95
52 WEEK LOW
5.53
MARKET CAP
519.83M
P/E (TTM)
-8.8103
1D
5D
1M
3M
1Y
5Y
Is Aldeyra Therapeutics Inc (ALDX) A Good Stock To Buy?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshl...
Insider Monkey · 10h ago
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
LEXINGTON, Mass., July 29, 2021--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights...
Business Wire · 18h ago
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Zacks · 07/21 15:13
Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate
Benzinga · 07/20 13:19
BRIEF-Aldeyra Therapeutics Receives Orphan Drug Designation From The U.S. Food And Drug Administration For ADX-2191 To Treat Primary Vitreoretinal Lymphoma
reuters.com · 07/20 12:56
Aldeyra Therapeutics shares rise on ADX-2191 FDA orphan drug status
Aldeyra Therapeutics (ALDX) announces that the U.S. FDA has granted orphan drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of primary vitreoretinal lymphoma ((PVRL)), a rare and aggressive form
Seekingalpha · 07/20 12:16
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company for ADX-2191 (methotrexate for intravitreal injection) for the treatment of primary vitr...
Business Wire · 07/20 12:00
Aldeyra Therapeutics Wins FDA Orphan Drug Designation for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
MT Newswires · 07/20 09:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALDX. Analyze the recent business situations of Aldeyra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALDX stock price target is 25.67 with a high estimate of 32.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 152
Institutional Holdings: 34.23M
% Owned: 59.39%
Shares Outstanding: 57.63M
TypeInstitutionsShares
Increased
30
8.88M
New
33
5.18M
Decreased
24
2.98M
Sold Out
21
1.73M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Other
Stephen Machatha
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Neal Walker
No Data
About ALDX
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.